David C. Collymore, MD, MBA, believes the field of personalized medicine has seen tremendous developments over the last 5 to 10 years, especially in oncology care.
“The role of genetic testing in both screening and treatment has received a lot of publicity in oncology, particularly in breast cancer,” he said, adding that genetic testing has been integrated into clinical care for the diagnosis of breast cancer to detect specific mutations in tumors. Dr Collymore explained that although it’s not yet the standard of care in screening for cancer risk, individuals have taken it upon themselves to undergo genetic testing to determine their risk of developing cancer.
“Angelina Jolie, who had prophylactic surgery, is a prominent example of this,” Collymore said. He then narrated a personal story of an acquaintance who, being aware of a strong family presence of breast and ovarian cancer, underwent genetic testing herself, followed by prophylactic surgery.
While the field of oncology has seen a lot of advances with respect to screening and treatment based on genetic testing, Dr Collymore believes that other areas such as diabetes and hypertension have also found use for this tool.
In terms of the impact on outcomes, he referenced older studies with tamoxifen in the treatment of breast cancer. “They found that a significant proportion of patients did not respond to treatment [with tamoxifen], which was a major advancement. But there is still a lot of work left to be done to show that it is cost effective,” Dr Collymore said.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More